HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Reimbursement remains ‘difficult issue’ in CAR T-cell therapy rollout


Should patients with ALL undergo HSCT after CAR T-cell therapy?


A sad week

John Sweetenham, MD

Pharmacology Consult

Differences in pharmacology, toxicities key to clinical use of PARP inhibitors

Jai N. Patel, PharmD, BCOP

Meeting News

Atezolizumab plus bevacizumab extends PFS in metastatic renal cell carcinoma

Docetaxel improves quality of life for men with prostate cancer

Persistent opioid use common after lung cancer surgery

High body fat, even with normal BMI, increases breast cancer risk

Poor sleep quality associated with higher BMI in children

Rise in Canadian obesity rate may increase country’s cancer burden

Survey: Fewer than 30% of oncologists ‘very comfortable’ treating severe immune-related adverse events

Nivolumab demonstrates antitumor activity for HIV-positive Kaposi sarcoma

Right-sided colorectal tumors have worse outcomes

Sorafenib plus transarterial chemoembolization improves PFS in unresectable hepatocellular carcinoma

Patient characteristics correlate with toxicity, response to CAR T-cell therapy in diffuse large B-cell lymphoma

Brentuximab vedotin combination superior to standard chemotherapy in Hodgkin lymphoma

Active surveillance shows benefit for rare Hodgkin lymphoma subtype

Combination therapy effective for diffuse large B-cell lymphoma

Reliance on emergency care for sickle cell disease pain highest among adolescents

Immunosuppressive therapy leads to transfusion independence for nearly 40% of patients with myelodysplastic syndrome

Idasanutlin active in refractory polycythemia vera

Atezolizumab-based triplet effective, but toxic, for follicular lymphoma

Analysis shows ‘no clear signal’ linking fedratinib to Wernicke’s encephalopathy in myeloproliferative neoplasms

Talazoparib improves PFS over chemotherapy for patients with BRCA mutations

Weight loss reduces breast cancer risk for postmenopausal women

Larger margin width reduces local recurrence for early-stage breast cancer

In the Journals Plus

Myeloablative allogeneic hematopoietic cell transplantation associated with significant cognitive decline

Dabrafenib plus trametinib first regimen to produce clinical activity in BRAF V600E-mutated anaplastic thyroid cancer

Physician recommendation drives use of chemoprevention for breast cancer

Olaparib maintenance therapy prolongs PFS for BRCA-mutated ovarian cancer

Most older patients with advanced lung cancer receive no therapy

Family history, disease stage key in determining need for inherited prostate cancer genetic testing

Failure of lomustine, bevacizumab for progressive glioblastoma likely to cause paradigm shift

In the Journals

Cancer immunotherapy safe for patients with rheumatic diseases

Patients with glioblastoma fare better when treated at high-volume facilities

FDA News

FDA approves Lutathera for gastroenteropancreatic neuroendocrine tumors

FDA updates Tasigna label to include information on discontinuation

FDA expands approval of Gilotrif for advanced lung cancer with uncommon EGFR mutations

FDA grants breakthrough therapy designation to Kisqali for certain premenopausal women with breast cancer

Pembrolizumab yields positive outcomes in trials for melanoma, NSCLC

Glowing tumor dye may distinguish tumors from healthy tissue among patients with head, neck cancers

Lymphadenectomy may not add benefit in high-risk renal cell carcinoma

GC4419 reduces severe oral mucositis in head and neck cancer

ProscaVax reduces prostate cancer disease progression

Stem cell transplantation specialist joins Fred Hutchinson Cancer Research Center

American Institute for Cancer Research funds studies to assess link between lifestyle, malignancy

ASCO announces new membership roles

Radiologist joins Fox Chase Cancer Center

National Academy of Science to honor immunotherapy pioneer